Please assess the completion status of the following clinical trial:

Trial Title: A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria include:~* Moderate to severe acute pain for which parenteral opioid therapy is warranted~* Able to understand and comply with the procedures and study requirements, and to provide written informed consent before any study procedure.~Exclusion Criteria include:~* Clinically significant medical, surgical, postsurgical, psychiatric or substance abuse condition or history of such condition that would confound the interpretation of safety, tolerability, or efficacy data in the study.~* Hemodynamic instability or respiratory insufficiency.~* Advanced cancer in palliative or end-of-life care.~* Another current painful condition (other than acute pain for which parenteral opioid therapy is warranted) that would confound the interpretation of safety, tolerability, or efficacy data in the study.~* Clinically significant, immune-mediated hypersensitivity reaction to opioids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TRV130 (Type: EXPERIMENTAL): For clinician-administered bolus dosing, TRV130 initial dose is administered and supplemental dosing is available, if clinically indicated. Subsequent doses may be administered every 1 to 3 hours as needed.~For PCA dosing, the TRV130 regimen consists of a loading dose, a demand dose, and a lockout interval.

Based on this trial design, predict the completion outcome and termination type (if applicable).